Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 + anlotinib vs chemotherapy in second-line advanced biliary tract cancer
CTR20212456Phase 3Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of benmelstobart in biliary cancer (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Overall survival (OS). Started Oct 2021; status: terminated.
02
Drugs
benmelstobart
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20212456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212456.